PMID- 36200523
OWN - NLM
STAT- MEDLINE
DCOM- 20221220
LR  - 20230320
IS  - 1529-8019 (Electronic)
IS  - 1396-0296 (Linking)
VI  - 35
IP  - 12
DP  - 2022 Dec
TI  - Efficacy of diammonium glycyrrhizinate in the treatment of rosacea with papules 
      and pustules: A randomized, double-blind, placebo-controlled study.
PG  - e15905
LID - 10.1111/dth.15905 [doi]
AB  - Rosacea is a kind of chronic inflammatory skin disease that usually occurs in the 
      middle of the face. Diammonium glycyrrhizinate (DG), an effective monomer 
      component extracted from licorice, has extensive anti-inflammatory, antioxidant, 
      anti-allergic, and immunomodulatory effects. There is no research on its 
      therapeutic effect on rosacea. In this study, we divided rosacea patients mainly 
      characterized by papules and pustules randomly into three groups. Group A 
      received clarithromycin 500 mg once a day, isotretinoin 10 mg once a day; Group B 
      received DG 150 mg three times a day, other medicines were the same as Group A; 
      Group C received clarithromycin 250 mg once a day, isotretinoin 10 mg once every 
      2 days, and DG 150 mg three times a day. All patients' symptom scores and 
      laboratory tests were evaluated when followed up. We found that DG combined with 
      clarithromycin and isotretinoin in the treatment of rosacea was more effective 
      and quicker than clarithromycin and isotretinoin alone. Moreover, half common 
      dosage of clarithromycin and isotretinoin combined with DG could achieve the same 
      therapeutic effect as the conventional dose, and brought about lower incidences 
      of adverse events (AEs). Therefore, it is recommended to use half common dosage 
      of routine medication combined with DG for rosacea patients mainly characterized 
      by papules and pustules.
CI  - (c) 2022 Wiley Periodicals LLC.
FAU - Xie, Yuming
AU  - Xie Y
AD  - Department of Dermatology, The Second Xiangya Hospital, Central South University, 
      Changsha, China.
FAU - Huang, Junke
AU  - Huang J
AD  - Department of Dermatology, The Second Xiangya Hospital, Central South University, 
      Changsha, China.
FAU - Liu, Juan
AU  - Liu J
AD  - Department of Dermatology, The Second Xiangya Hospital, Central South University, 
      Changsha, China.
FAU - Zhang, Qing
AU  - Zhang Q
AUID- ORCID: 0000-0001-8309-349X
AD  - Department of Dermatology, The Second Xiangya Hospital, Central South University, 
      Changsha, China.
LA  - eng
GR  - 81872533/National Natural Science Foundation of China/
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20221017
PL  - United States
TA  - Dermatol Ther
JT  - Dermatologic therapy
JID - 9700070
RN  - EH28UP18IF (Isotretinoin)
RN  - 6FO62043WK (Glycyrrhizic Acid)
RN  - H1250JIK0A (Clarithromycin)
SB  - IM
MH  - Humans
MH  - Isotretinoin
MH  - Glycyrrhizic Acid/adverse effects
MH  - Clarithromycin/therapeutic use
MH  - *Rosacea/diagnosis/drug therapy
MH  - Double-Blind Method
MH  - *Exanthema/chemically induced
OTO - NOTNLM
OT  - clarithromycin
OT  - combined treatment
OT  - diamine glycyrrhizinate
OT  - isotretinoin
OT  - rosacea
EDAT- 2022/10/07 06:00
MHDA- 2022/12/21 06:00
CRDT- 2022/10/06 05:43
PHST- 2022/09/18 00:00 [revised]
PHST- 2022/06/27 00:00 [received]
PHST- 2022/09/27 00:00 [accepted]
PHST- 2022/10/07 06:00 [pubmed]
PHST- 2022/12/21 06:00 [medline]
PHST- 2022/10/06 05:43 [entrez]
AID - 10.1111/dth.15905 [doi]
PST - ppublish
SO  - Dermatol Ther. 2022 Dec;35(12):e15905. doi: 10.1111/dth.15905. Epub 2022 Oct 17.